There was no documentation available for the handling and disposition of reports of patient problems, complaints, adverse drug reactions, drug product or device defects, and other adverse events reported.
Inspection Record
New England Compounding Center — FDA 483 Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
For the preparation of sterile drug products distributed by your firm (such as those intended for injection), there is no adequate documentation available to verify that they meet set standards (such as specifications and/or USP limits if applicable) at the time they are distributed or for the shelf life (expiration dating period) of these products.
There are no written procedures pertaining to the handling of complaints, nor does your firm maintain a complaint file.
About this record
Extracted automatically from the document US FDA published on 2024-01-17. The source is available at the link above.
This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.
Translation and classification are automated and may differ in nuance from the source.
